► End-tidal capnography during endoscopic retrograde cholangiopancreatography (ERCP) is reported to be useful. However, the detection of EtCO 2 during full endoscopic procedures using currently available sidestream-style products has been reported to be difficult because of the blockage of the sampling tube with saliva or secretions, undetectable shallow breathing, or tachypnoea, with sampling errors caused by high oxygen concentration.
What are the new findings?
► The newly developed mainstream capnometer system for ERCP under CO 2 insufflation is useful and reliable based on this pilot study.
How might it impact on clinical practice in the foreseeable future?
► Based on this research, reliable detection of respiratory arrest during ERCP treatment under sedation is expected to be possible. This has an impact on patient management during endoscopic treatment.
AbSTrACT background and aims
There is a need to safely achieve conscious sedation during endoscopic retrograde cholangiopancreatography (ERCP). We evaluated the safety and feasibility of a mainstream capnometer system to monitor apnoea during ERCP under CO 2 insufflation. Methods Non-intubated adult patients undergoing ERCP-related procedures with intravenous sedation were enrolled. End-tidal CO 2 (EtCO 2 ) was continuously monitored during the procedure under CO 2 insufflation using a mainstream capnometer system, comprising a capnometer and a specially designed bite block for upper gastrointestinal endoscopy and ERCP. Oxygen saturation (SpO 2 ) was also monitored continuously during the procedure. In this study, we evaluated the safety and feasibility of the capnometer system. results Eleven patients were enrolled. Measurement of EtCO 2 concentration was possible from the beginning to the end of the procedure in all 11 cases. There was no measurement failure, dislocation of the bite block, or adverse event related to the bite block. Apnoea linked to hypoxaemia occurred five times (mean duration, 174.4 s). Conclusion This study confirmed that apnoea was detected earlier than when using a percutaneous oxygen monitor. Measurement of EtCO 2 concentration using the newly developed mainstream capnometer system was feasible and safe even under CO 2 insufflation.
IntroductIon
Given the continued increase in the complexity of interventional endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) for pancreatobiliary disorders, endoscopists encounter a larger number of patients requiring procedural sedation. 1 In Japan, conscious sedation during such procedures is mainly managed by endoscopists themselves, rather than by anaesthesiologists. Effective conscious sedation and analgesia during endoscopic procedures provides relief of suffering and frequently leads to a successful and shorter procedure. However, agents for sedation and/or analgesia can result in adverse effects. Therefore, significant attention has been paid to safely achieve conscious sedation during ERCP.
Hypoxaemia is the most frequent adverse effect of conscious sedation during endoscopic procedures. 2 Causes of hypoxaemia are considered to be apnoea caused by respiratory depression or comorbid respiratory dysfunction, such as chronic obstructive pulmonary disease. Hypoxaemia can lead to unexpected cardiac arrest and/or brain injury. It has been reported that hypoxaemia follows apnoea during sedation, Open access and as such, early detection of apnoea may decrease hypoxaemia. 3 End-tidal capnography is a non-invasive method to detect depressed respiratory activity by optimal assessment of CO 2 throughout the respiratory cycle. End-tidal capnometry has been reported to be useful in the intensive care unit. 4 However, its reliability and safety during endoscopic procedures have not been confirmed because of insufficient evidence.
5-10 Detection of end-tidal CO 2 (EtCO 2 ) during full endoscopic procedures using currently available sidestream-style products has been reported to be difficult owing to blockage of the sampling tube with saliva or secretions, undetectable shallow breathing, or tachypnoea, with sampling errors caused by high oxygen concentration.
11 New endoscope-dedicated capnometer systems are expected to improve these weaknesses.
Recently, a mainstream capnometer system for patients undergoing upper endoscopy and requiring oxygen was developed with the technological innovation of CO 2 detector miniaturisation. 12 13 A sidestream capnometer transports a portion of the patient's respired gases from the sampling site, through a long sampling tube, to a sensor, whereas a mainstream capnometer does not transport gas away from the sampling site (figure 1). The CO 2 concentration is measured directly by a sensor on the nose, and its usefulness has been reported. 11 Therefore, we applied this mainstream capnometer system to endoscopic procedures. The sensor on the bite block can measure mixed CO 2 from the mouth and nose through the airway of the bite block. Because there is neither obstruction by saliva nor time lag, this newly developed mainstream capnometer is expected to measure CO 2 more accurately than a conventional sidestream capnometer. In this pilot study, we examined the safety and feasibility of this new capnometer system in the clinical setting.
PatIents and methods Patients and procedure
Patients undergoing ERCP-related procedures at our university hospital were enrolled with written informed consent. Endoscopic procedures under room air and CO 2 insufflation were performed in the general endoscopy room without anaesthesiologists. All patients were administered flunitrazepam 0.2 mg and pethidine 35 mg intravenously under EtCO 2 , oxygen saturation (SpO 2 ), electrocardiographic, and blood pressure monitoring. Investigators checked the monitors throughout the procedure and intervened with body shaking and O 2 supply or antagonist for apnoea or hypoxaemia. Apnoea was defined as 15 s suspension of EtCO 2 elevation. Hypoxaemia was defined as a 5% decrease before the procedure. Events within 3 min of each other were defined as a single event. The study was registered in UMIN (UMIN000029407), and the first patient was enrolled on 7 December 2016.
newly developed capnometer
The cap-ONE bite block (YG-227T; Nihon Kohden, Tokyo, Japan) can deliver oxygen while measuring mainstream EtCO 2 during endoscopic procedures (figure 2). It comprises the mainstream capnometer cap-ONE (TG-980P; Nihon Kohden), nasal adapter, oxygen cup, and mouthpiece. The nasal adapter collects exhaled nasal flow into a measurement cell, while the oxygen cup delivers oxygen through the patient's nose and has a sponge to scatter oxygen for accurate CO 2 monitoring. The mouthpiece has a double-layer conduit to open the patient's mouth as well as to collect oral exhaled CO 2 . It also has an oxygen port, which can supply oxygen through the mouth. Measurement of CO 2 concentration was possible from the beginning to the end of the procedure in all 11 cases, even though temporary spikes in CO 2 were observed at the time of inserting and extracting the endoscope and belching ( figure 3 ). There was no detection failure of the CO 2 wave. There were no harmful capnometer-related complications, such as discomfort when wearing. Apnoea Open access occurred seven times in seven patients, and hypoxaemia was linked to apnoea five times in five patients (figure 4). Mean delay from apnoea to hypoxaemia was 174.4±104.3 s. Hypoxaemia requiring intervention occurred five times in four patients. Hypoxaemia requiring intervention linked to apnoea occurred two times in two patients. Figure 5 shows a reduced view of the capnometer waveform in these two patients. Hypoxaemia without preceding apnoea occurred three times in two patients (table 2) .
dIscussIon
This study is the first pilot study on the feasibility and safety of a novel mainstream capnometer system during interventional endoscopy. This study showed that it was possible to measure EtCO 2 throughout the endoscopic procedure and accurately detect apnoea using this capnometer. There were also no harmful complications related to the capnometer. Conventional percutaneous CO 2 monitors are not so effective during endoscopic procedures because of their low measurement accuracy and measurement failure; further, their set-up is labour intensive and they require a prolonged stabilisation time .
14 Capnometer is considered to have a higher measurement accuracy than percutaneous CO 2 monitors because it directly reflects changes in respiration.
Disadvantages of the currently used sidestream capnometer include delayed response due to the length of the sampling tube, obstruction by water or saliva, and measurement inaccuracies due to large oxygen flow. 15 16 On the other hand, the newly developed mainstream capnometer system can measure exhaled CO 2 directly around the mouth and nose without a delayed response and can prevent tube obstruction by water or saliva. Therefore, the mainstream capnometer is expected to be reliable with more accurate data, especially during ERCP, which is often performed in patients with shallow breathing and a lot of saliva. Fortunately, in this study, we successfully measured EtCO 2 during the procedure under CO 2 insufflation without detection failure.
Open access Figure 5 Waveform of hypoxaemia linked to apnoea. These are representative data of apnoea preceding hypoxaemia. Conventionally, there was concern about discomfort wearing the mainstream capnometer because of its large size, but the cap-ONE is small enough to fit into the bite block.
Integrating capnography into patient-monitoring protocols for endoscopic procedures with moderate sedation, which typically consist of a benzodiazepine and narcotic analgesic, has not been shown to improve patient safety. However, there is evidence supporting its use in procedures targeting deep sedation. Also, use of a capnometer for EUS and ERCP has not been recognised as a standard method for monitoring in the American Society for Gastrointestinal Endoscopy guideline. 1 In one trial comparing capnometer versus oximetry monitoring in patients undergoing EUS or ERCP, the frequency of hypoxaemia was significantly reduced in patients with capnography. 7 However, there is another trial with contradictory results. In the latter study, per-protocol analysis excluding cases of mismeasurement due to capnometer problems revealed that the frequency of hypoxaemia was significantly reduced. 8 The reliability of the mainstream capnometer is expected to be generalised based on more evidence.
Therefore, it is assumed that capnometry may reduce the incidence of hypoxaemia when applied correctly. There are some risk factors for hypoxaemia during endoscopy, which have been pointed out in previous studies, such as age, high body mass index, history of sleep apnoea, and increased doses of sedatives. 9 Apnoea is also an independent risk factor for hypoxaemia, and a capnometer may reduce hypoxaemia due to apnoea. In our study, apnoea preceding hypoxaemia was detected in 5 of 11 cases, and it seems that intervention, such as physical stimulation or increased O 2 inhalation, may prevent the subsequent decrease in SpO 2 .
The limitation of this research is that it included only a small number of cases. Thus, there is a possibility that cases of measurement failure may occur as the number of cases increases. In addition, because sedation depth during ERCP differs depending on the country and facility, our study reflects data under specific conditions. However, apnoea preceding hypoxaemia definitely exists. If we can properly apply the capnometer and receive accurate data, the use of a capnometer during ERCP procedures is useful for reducing hypoxaemia by detecting apnoea earlier.
Based on the result of this pilot study, a randomised controlled trial comparing capnometer monitoring and standard monitoring is currently in progress.
Open access conclusIon It is suggested that during ERCP, the mainstream method using our novel capnometer may be more accurate and useful than the sidestream method. Although this was a study of only a few cases, it suggests that a mainstream capnometer is useful for early detection of hypoxaemia by apnoea detection and its prevention. We would like to evaluate its usefulness in randomised trials of numerous cases in the future.
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